Operators

Jeno Gyuris, Ph.D.

Jeno is a seasoned biotech professional with over three decades of experience in the industry. Throughout his career, his primary focus has been translating promising scientific discoveries into impactful therapies and fostering the growth of early-stage start-up companies. Jeno has gained extensive scientific leadership and company-building experience, having assembled, led, and mentored high-performing R&D organizations. […]

Jeno Gyuris, Ph.D. Read More »

May Han, Ph.D.

Dr. Han (May) has over 20 years of experience in drug discovery and development. May’s experience includes being both a drug program manager and a scientific team lead, encompassing more than 20 programs across a variety of drug modalities, including small molecule, complex biologics, cell therapies. She worked at Millennium Pharmaceuticals, AVEO and Novartis in

May Han, Ph.D. Read More »

Kenzie Maclsaac, Ph.D.

Dr. MacIsaac is a Partner at Cure Ventures. Kenzie’s career spans over 13 years in drug discovery working at the cutting edge of genetics, genomics, and bioinformatics to solve pressing problems in human health. Prior to joining Cure Ventures, Dr. MacIsaac served as a Senior Director at Bristol Myers Squibb where he built out the

Kenzie Maclsaac, Ph.D. Read More »

Annie Mitsak, Ph.D.

Annie is an experienced investment professional with over ten years of academic licensing and venture investing experience. Prior to joining Cure, Annie was an independent consultant to several VC-backed biotech companies, within oncology, gene therapy and RNA therapeutics. Annie spent over six years on the investment team at Omega Funds, where she sourced, diligenced and

Annie Mitsak, Ph.D. Read More »